T2E-negative PCa (n = 230) | T2E-positive PCa (n = 266) | ||||||
---|---|---|---|---|---|---|---|
Variables | No. | % | Mean (SD) | No. | % | Mean (SD) | P valuea |
Age at diagnosis (years) | – | – | 59.5 (7.1) | – | – | 56.8 (6.8) | <0.01 |
Race | <0.01 | ||||||
African-American | 29 | 12.6 | – | 14 | 5.3 | – | – |
European-American | 201 | 87.4 | – | 252 | 94.7 | – | – |
Gleason score | <0.01 | ||||||
≤6 | 92 | 40.0 | – | 141 | 53.0 | – | – |
7 (3 + 4) | 89 | 38.7 | – | 93 | 35.0 | – | – |
7 (4 + 3) | 29 | 12.6 | – | 15 | 5.6 | – | – |
≥8 | 20 | 8.7 | – | 17 | 6.4 | – | – |
Pathological stage | 0.70 | ||||||
Local (pT1/pT2) | 159 | 69.1 | – | 179 | 67.3 | – | – |
Regional (pT3) | 71 | 30.9 | – | 87 | 32.7 | – | – |
PSA (ng/mL) at diagnosis | 0.06 | ||||||
<4 | 26 | 12.0 | – | 52 | 20.6 | – | – |
4– < 10 | 138 | 63.6 | – | 156 | 61.9 | – | – |
10– < 20 | 38 | 17.5 | – | 28 | 11.1 | – | – |
≥20 | 15 | 6.9 | – | 16 | 6.3 | – | – |